Bringing a combination product from late-stage clinical trials to the commercial market is not a simple handoff. It is a carefully managed transition involving drug, biologic, medical device, packaging, quality, manufacturing, and regulatory requirements.
Examples of combination products include prefilled syringes, autoinjectors, drug-eluting stents, inhalers, and wearable drug-delivery systems. These products must meet the rules that apply to their main mode of action, while also addressing requirements connected to their other components.
For organizations developing Combination Products, success depends on planning for commercial needs before clinical development is complete. Waiting until the final stages can lead to stability problems, repeated testing, delayed regulatory submissions, and costly manufacturing changes.
Understanding the Clinical-to-Commercial Gap
Clinical development focuses mainly on showing that a product is safe, effective, and usable under controlled trial conditions.
Commercialization has broader demands. The final product must perform consistently across:
- Large-scale manufacturing
- Long-term storage
- Shipping and distribution
- Different climates and regions
- Automated packaging lines
- Real-world patient use
This difference creates a gap between the clinical product and the market-ready product.
During trials, a company may use small production batches, temporary labels, manual assembly, or prototype devices. These methods may be acceptable for clinical use, but they are usually not suitable for full commercial production.
The goal is to close this gap without introducing changes that affect product quality, safety, or regulatory approval.
Stability Requirements Become More Demanding
Stability testing determines how long a product remains safe, effective, and functional under specific storage conditions.
Stability During Clinical Development
Clinical-stage studies are often designed to support the expected length of the trial. They may include:
- Shorter testing periods, such as 6 to 12 months
- Limited environmental stress testing
- Small or pilot-scale production batches
- Temporary packaging configurations
- Prototype or early-stage device components
These studies may be enough to support investigational use. However, they usually do not provide all the information needed for commercial approval.
Commercial Stability Expectations
Commercial stability programs must support the product’s complete shelf life, which may be 18 to 36 months or longer.
They commonly require:
- Long-term, real-time stability studies
- Accelerated and stress testing
- Multiple commercial-scale production lots
- Evaluation of drug, container, device, and packaging interactions
- Temperature excursion studies
- Transportation and distribution testing
For combination products, stability must cover the complete drug-device system. The drug may remain chemically stable, but the device must also continue to deliver the correct dose throughout the product’s shelf life.
How Packaging Can Affect Product Performance
Packaging is more than a box that holds the product. It can affect stability, safety, usability, and device performance.
During clinical trials, packaging may be simple because the product is used in small quantities and controlled environments. Commercial packaging must meet much wider requirements.
Commercial Packaging May Need:
- Branding and final artwork
- Tamper-evident features
- Child-resistant designs
- Multilingual information
- Serialization and product tracking
- Compatibility with automated packaging equipment
- Protection during international transportation
Even small packaging changes can create new risks.
For example:
- Switching from glass to plastic may change moisture or oxygen exposure.
- Silicone oil inside a syringe may interact with a biologic product.
- Transparent packaging may increase the risk of light-related damage.
- A new label adhesive may affect the container under certain conditions.
- A redesigned tray may provide less protection during shipping.
These changes may require bridging studies to prove that the commercial package performs as well as the clinical version.
Labeling Becomes More Complex at Launch
Clinical labels are often basic. They may include only the product code, storage instructions, dosing information, and a statement explaining that the product is for investigational use.
Commercial labeling must provide much more information.
It may include:
- Approved product name and strength
- Warnings and precautions
- Instructions for use
- Device symbols and markings
- Patient information
- Multiple languages
- Serial numbers or two-dimensional barcodes
- Anti-counterfeiting features
For combination products, labeling may also serve as a safety control. Clear instructions can help prevent incorrect dosing, improper device activation, or unsafe disposal.
When label content, layout, graphics, or language changes, the development team must evaluate whether users can still understand and follow the instructions correctly.
Additional usability testing may be needed when changes affect a critical task.
When Verification and Validation Must Be Updated
Verification confirms that a product meets its defined requirements. Validation confirms that the product works for its intended users and intended purpose.
Changes made during commercialization may affect earlier verification and validation results.
Common examples include:
- New packaging materials
- Revised device components
- Different label layouts
- Automated assembly processes
- New manufacturing equipment
- Serialization software
- Updated instructions for use
A change from manual clinical labeling to automated commercial labeling may introduce cameras, software, databases, and inspection systems. These systems must be tested to confirm that labels are accurate and traceable.
A Risk-Based Review Should Include:
- Comparing clinical and commercial configurations
- Identifying differences in materials and processes
- Assessing effects on product quality and user safety
- Determining whether existing test results remain valid
- Conducting targeted testing when needed
- Documenting the reason for full, partial, or no re-validation
Not every change requires complete re-validation. However, every meaningful change should be reviewed and supported by clear evidence.
Why Cross-Functional Planning Matters
No single department can manage the clinical-to-commercial transition alone.
Successful programs require cooperation among:
- Pharmaceutical scientists
- Device engineers
- Quality assurance teams
- Regulatory specialists
- Human factors experts
- Manufacturing engineers
- Packaging professionals
- Supply chain teams
Commercial packaging experts should be involved before the clinical configuration is finalized. Device engineers should understand formulation and stability limits. Regulatory teams should review major changes before they are implemented.
Useful practices include:
- Creating one integrated development timeline
- Reviewing packaging and stability plans together
- Including commercial labels in late-stage usability studies
- Planning verification and process validation in parallel
- Discussing major changes with regulatory authorities when necessary
- Assigning clear ownership for each activity
Cross-functional planning helps prevent late discoveries that could delay submission or launch.
Building a Stronger Path to Market
The transition from clinical trials to commercial launch should be treated as a planned bridge rather than a last-minute jump.
Organizations can reduce risk by preparing commercial packaging early, expanding stability programs, reviewing labeling as a safety control, and assessing how each change affects prior testing. The strongest programs maintain clear links between the clinical product, commercial design, manufacturing process, regulatory strategy, and intended user experience.
Ventura Solutions helps medical device and combination product companies manage these complex transitions through regulatory, quality, design and development, staffing, and training support. By working with experienced professionals early, organizations can reduce rework, strengthen submission readiness, and move toward commercial launch with greater confidence.
Frequently Asked Questions
1. What makes combination products difficult to commercialize?
They must meet requirements for more than one regulated product type. A drug-device product, for example, must address pharmaceutical quality as well as device design, usability, and performance.
2. Can the commercial product be different from the clinical version?
Some differences may be acceptable, but they must be carefully evaluated. Significant changes may require bridging studies, additional stability testing, or updated verification and validation.
3. Why is commercial stability testing longer?
Commercial stability data must support the full labeled shelf life of the product. It must also reflect final packaging, manufacturing processes, storage conditions, and distribution risks.
4. Do packaging changes always require re-validation?
No. The amount of testing depends on the level of risk. A documented assessment should determine whether full, partial, or no re-validation is appropriate.
5. Why are instructions for use important?
Instructions for use help patients and healthcare professionals operate the product correctly. They may serve as an important control for reducing use-related risks.
6. When should commercial planning begin?
Commercial planning should begin during clinical development, not after trials are complete. Early planning gives teams time to address packaging, stability, labeling, manufacturing, and regulatory requirements.
